Effects of right ventricular dysfunction on exercise capacity and quality of life and associations with serum NT-proBNP levels in COPD: An observational study

Anadolu Kardiyoloji Dergisi

Volumn 14, Issue 4, 2014, Pages 370-377

  Şahin Özdemirel, Tuǧce ^a   Sariņ Ulaşli, Sevinç ^b   Yetiş, Begüm ^c   Karaçaǧlar, Emir ^c   Bayraktar, Nilüfer ^c   Ulubay, Gaye ^c  

^a Ataturk Chest Disease and Thoracic Surgery Education and Research Hospital Ankara   (Turkey)

^b AFYON KOCATEPE UNIVERSITY   (Turkey)

^c BASKENT UNIVERSITY   (Turkey)

Author keywords

Cardiopulmonary exercise testing; COPD; NT proBNP; Pulmonary hypertension; Quality of life; Right ventricular dysfunction

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ANAEROBIC THRESHOLD OXYGEN UPTAKE; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CARDIOPULMONARY EXERCISE TEST; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OXYGEN CONSUMPTION; PEAK OXYGEN UPTAKE; QUALITY OF LIFE; SHORT FORM 36; TOTAL LUNG CAPACITY; BLOOD; ENDURANCE; PATHOPHYSIOLOGY; PSYCHOLOGY;

BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PHYSICAL ENDURANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84903152944     PISSN: 13028723     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2014.4687     Document Type: Article

References (38)

1. Global strategy for diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease: updated 2009.
2. Takaruka M, Harada T, Fukuno H, Okushi H, Taniguchi T, Sawada S, et al. Echocardiographic detection of occult cor pulmonale during exercise in patients with chronic obstructive pulmonary disease. Echocardiography 1999; 16: 127-34.
3. Higham MA, Dawson D, Joshi J, Nihoyannopoulos P, Morrell NW. Utility of echocardiography in assesment of pulmonary hypertension secondary to COPD. Eur Respir J 2001; 17: 350-5.
4. Miyahara Y, Ikeda S, Yoshigana T, Yamaguchi K, Nishimura-Shirono E, Yamasa T, et al. Echocardiographic evaluation of right cardiac function in patients with chronic pulmonary diseases. Jpn Heart J 2001; 42: 483-93.
5. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202-9.
6. Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG. Natriuretic peptides, respiratory disease, and the right heart. Chest 2004; 126: 1330-6.
7. Karakiliç E, Kepez A, Abali G, Coşkun F, Kunt M, Tokgözoǧlu L. The relationship between B-type natriuretic peptide levels and echocardiographic parameters in patients with heart failure admitted to the emergency department. Anadolu Kardiyol Derg 2010; 10: 143-9.
8. Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J 2010; 51: 151-63.
9. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-68.
10. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al; ATS/ERS Task Force.Standardisation of spirometry. Eur Respir J 2005; 26: 319-38.
11. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-67.
12. Parisi A F, Moynihan P F, Feldman CL, Folland ED. Approaches to determination of left ventricular volume and ejection fraction by real-time two-dimensional echocardiography. Clin Cardiol 1979; 2: 257-63.
13. Chemla D, Castelain V, Hervè P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002; 20: 1314-31.
14. Yared K, Noseworthy P, Weyman AE, McCabe E, Picard MH, Baggish AL. Pulmonary artery acceleration time provides an accurate estimate of systolic pulmonary arterial pressure during transthoracic echocardiography. J Am Soc Echocardiogr 2011; 24: 687-92.
15. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105: 1387-93.
16. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23: 685-713.
17. Wasserman K, Hansen JE, Sue DY, Whipp BJ, Casaburi R. Principles of exercise testing and interpretation.3rd ed Vol. 10. Baltimore: Lippincott Williams &Wilkins, 1999.
18. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997; 127: 1072-9.
19. Ulubay G, SarinÇ Ulaşli S, Akinci B, Görek A, Akçay S. Assessment of relation among emotional status, pulmonary function test, exercise performance, and quality of life in patients with COPD. Tuberk Toraks 2009; 57: 169-76.
20. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
21. Karabulut A, and Lltimur K. Saǧ ventrikül diyastolik fonksiyonlari{dotless}ni{dotless}n kronik obstüktif akciǧer hastali{dotless}ǧi{dotless}ni{dotless}n evrelerine göre deǧerlendirilmesi. Dicle Ti{dotless}p Dergisi 2005; 32: 145-8.
22. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-94.
23. Leuchte HH, Neurohr C, Baumgartner R, Holzapfel M, Giehrl W, Vogeser M, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170: 360-5.
24. Lang CC, Coutie WJ, Struthers AD, Dhillon D.P, Winter JH, Lipworth BJ. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci 1992; 83: 529-33.
25. Chi SY, Kim EY, Ban HJ, Oh IJ, Kwon YS, Kim KS, et al. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung 2012; 190: 271-6.
26. Bozkanat E, Tozkoparan E, Baysan O, Deniz O, Çiftçi F, Yokusoǧlu M. The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease. J Int Med Res 2005; 33: 537-44.
27. Bando M, Ishii Y, Sugiyama Y, Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999; 93: 507-14.
28. Maisel AS. B type natriuretic peptide (BNP) levels: diagnostic and therapeutic potential. Rev Cardiovascular Med 2001; 2: 13-8.
29. Stamm JA, Belloli EA, Zhang Y, Bon J, Sciurba FC, Gladwin MT. Elevated N-terminal pro-brain natriuretic peptide is associated with mortality in tobacco smokers independent of airflow obstruction. PLoS One 2011; 6: e27416.
30. Gallagher CG. Exercise limitation and clinical exercise testing in chronic obstructive pulmonary disease. Clin Chest Med 1994; 15: 305-26.
31. Nici L. Mechanisms and measures of exercise intolerance in chronic obstructive pulmonary disease. Clin Chest Med 2000; 21: 693-704.
32. O'Donnel DE, Revill S, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-7.
33. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
34. Krüger S, Graf J, Kunz D, Stickel T, Hanrath P, Janssens U. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 2002; 40: 718-22.
35. Eroǧlu S, Yildirir A, Bozbaş H, Aydinalp A, Ulubay G, Eldem O, et al. Brain natriuretic peptide levels and cardiac functional capacity in patients with dyspnea and isolated diastolic dysfunction. Int Heart J 2007; 48: 97-106.
36. Cuttica MJ, Shah SJ, Rosenberg SR, Orr R, Beussink L, Dematte JE, et al. Right heart structural changes are independently associated with exercise capacity in non-severe COPD. PLoS One 2011; 6: e29069.
37. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T, Izumi T. A comparison of the level of dyspnea vs. disease severity in indicating the health related quality of life of patients with COPD. Chest 1999; 116: 1632-7.
38. Katsura H, Yamada K, Kida K. Both generic and disease specific health-related quality of life are deteriorated in patients with underweight COPD. Respir Med 2005; 99: 624-30.